Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. - Wikidata - wikimedia - TriplyDB

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

http://www.wikidata.org/entity/Q33672541

about

Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure Viral quasispecies evolution Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection Standing genetic variation and the evolution of drug resistance in HIV Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1 Minority variants of drug-resistant HIV.Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression.Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.Improved detection of rare HIV-1 variants using 454 pyrosequencing.Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Clinical management of HIV drug resistance.Ongoing HIV Transmission and the HIV Care Continuum in North Carolina.Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq.

P2860

Q26851997-4BFBB3E7-D154-4D1E-89CA-5B1431D5F148 Q26853055-76D213DF-7F7D-4FC7-B904-7504EB395D1E Q27003431-CC2F8793-862D-4791-9BD5-2551D8D92C39 Q27013917-F2D8C29A-0DD9-40B2-817F-DED76864EBE4 Q28474221-38016B72-20CC-4D50-8E5C-6826C7645A6A Q28478134-2B3325B4-D0B0-4393-83A6-718C44C91FC4 Q28478459-81BFBAE6-0E76-461C-8093-7D06319B692E Q28478779-BF3FD17D-189F-4807-A439-485F55E436E9 Q28478934-5D6AA464-3EC3-4BD3-957C-1D0EF6288FB5 Q28484153-05B52BD3-EDAF-4103-8B61-CF513B02F83A Q28537608-58B259B5-DAE3-4944-A9B3-47C9CBEBB46F Q28538326-FF57ECDA-64CD-41ED-997A-D62CC6CA62BB Q28539186-4D2637B7-7B8A-4601-AB78-61B16A930DA8 Q28539368-3B8763BB-3E3D-4604-A318-128D571AD144 Q28541754-5442DC3F-A399-417F-84E4-22E82CFFFF7E Q28543986-3DC8D7C7-925A-4E77-98C7-BE0396D20C5C Q28550310-F0AB5CB4-9525-4CFF-AAEB-0ADEFCD9FF2F Q28552455-C368F81A-40D4-4C16-BC90-889DBFD2AE2A Q28553024-847A9394-C55D-4CD0-9C7E-44DCC830956F Q28554999-D2391EAF-73C2-41E2-85C0-FC732479564B Q33622927-7C5A52C0-3807-43C4-B60F-DFF6ED0FAAC8 Q33634625-17F0F075-05CE-4AEC-AF09-E78B8BBC9733 Q33927293-12E7CD55-CFBE-4741-BCCB-007FE15697B2 Q34047780-3CAF512E-DC6E-4402-AC17-A269119B21B7 Q34116836-C32463DF-7BA9-4943-8D21-68CF6C2CA9E6 Q34567556-B75EB492-1AD5-42BD-827F-B3257BFD9E70 Q34614542-5FA7C237-4AF4-4D18-9898-5527E745623E Q34785616-0C4998E2-6DC7-46DA-8F96-C455313FD7D5 Q35009489-B99C2C55-E9D0-484E-8C00-66544AE2AB9F Q35056873-D270ABD8-94D8-4F83-BAC1-0539487E4AFD Q35124860-0050ACF4-C180-4B51-9EEB-29BB36F18EF3 Q35140450-D206A31B-BF25-4695-B1B0-2D57195CFA7A Q35261045-EFF4ADDB-C997-46CA-932B-80422EFBA4EA Q35652703-A343983D-478C-465D-8EE4-72C54227A5C6 Q35694729-2CF458FD-7219-404A-BA48-14FD62E492CF Q35887051-11E71846-F773-4B53-A915-8D022095B7CA Q35944787-529F443F-30A8-497F-9FC7-986FAE738C08 Q36158371-B73BDC79-86B9-4F06-B75D-DC8CCB954041 Q36186007-D6547E62-88A3-417D-8DB6-750DE16CBFB0 Q36271817-A04106BC-637E-4C63-953C-53CC04A99B9F

P2860

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

http://www.wikidata.org/entity/Q33672541

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pre-existing minority drug-res ...... iretroviral treatment failure.

@ast

Pre-existing minority drug-res ...... iretroviral treatment failure.

@en

type

label

Pre-existing minority drug-res ...... iretroviral treatment failure.

@ast

Pre-existing minority drug-res ...... iretroviral treatment failure.

@en

prefLabel

Pre-existing minority drug-res ...... iretroviral treatment failure.

@ast

Pre-existing minority drug-res ...... iretroviral treatment failure.

@en

P1433

Q33672541-CAFCF23C-B338-47F6-8CC3-589FAF7B02D0

P1476

Q33672541-E1EF40A9-0520-4588-B49F-54504BAA0AD5

P2093

Q33672541-092ED03F-AE5C-414C-A2D4-DBC557E94A3B

Q33672541-13451267-DA40-42C8-A52D-E4C19167AFA8

Q33672541-2257AAAB-23CA-46BA-87D2-B3691E9BD869

Q33672541-2EC03743-BC84-4CF8-BFD1-D7DE9104DA53

Q33672541-3646E7E5-FA70-46EB-AB79-0F2C7A72FFA6

Q33672541-43213EAC-96DD-4582-B7F0-7802E723BD2A

Q33672541-5A65E760-63E6-41E6-BA3F-14C2618A5714

Q33672541-5DB3B48F-7DFA-4EB2-894F-8D69711500EE

Q33672541-5DB91DCE-7FA7-4B7B-AD4E-09A455CCCFB9

Q33672541-6876C86D-75DB-4E28-B613-8B467E22F6B8

P2860

Q33672541-0A71C8FC-E2DE-46B1-B2C0-F07D8B2E8B3D

Q33672541-120F9AA3-6C5D-4137-92BC-C148B25AD3B8

Q33672541-28A25294-AA4A-4CE4-975C-4407DBDFD9E9

Q33672541-2FD5A6F2-FC76-4BF3-BAAE-00FFCF54A001

Q33672541-3A022D2A-6D42-4B6D-9953-B8FAA0B708DC

Q33672541-3F229BE4-9370-4381-AA43-CB92BEE218B7

Q33672541-47436CAA-087C-40C7-A2B1-06DC14D6358A

Q33672541-4F7C4F04-A9A7-4D9D-B416-FBD23515AE9E

Q33672541-57B4E228-0C19-4617-85CE-9B5BCC1F7D2B

Q33672541-5A10FCBF-AD04-4C4C-B826-43C3FBFC731D

P304

Q33672541-2BC9CD40-0A4C-486E-9763-A86A39787030

P31

Q33672541-FDA48E40-14EE-4547-84ED-634FF972DA57

P356

Q33672541-B82B108E-E943-4CF7-837A-DE51995AD911

P407

Q33672541-E1E9711C-91B2-4C1B-AE93-29DBD0D73943

P433

Q33672541-19B674A2-85A5-4EC6-B4E2-DF40AE81B69C

P478

Q33672541-C5DD1430-7D18-4E9B-BED6-D62F704B0B5E

P577

Q33672541-FD855F31-3F2F-40C5-86C8-DE6A4C4C5AEC

P5875

Q33672541-701A45E2-4A8C-472E-BBA1-D5BED449ADB2

P698

Q33672541-E9782B67-CE87-441C-A01C-7F6C907ACBE3

P921

Q33672541-B510C121-F119-46BD-B563-768FE0555F70

P932

Q33672541-B3474F5A-AC47-4FAC-9FA1-D10D6B6387AF

P356

P1433

The Journal of Infectious Diseases

P1476

Pre-existing minority drug-res ...... iretroviral treatment failure.

@en

P2093

AIDS Clinical Trials Group (ACTG) A5095 Study Team

http://www.w3.org/2001/XMLSchema#string

Bruce R Schackman

http://www.w3.org/2001/XMLSchema#string

Cecilia Shikuma

http://www.w3.org/2001/XMLSchema#string

Christina M Lalama

http://www.w3.org/2001/XMLSchema#string

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Francoise Giguel

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Richard T D'Aquila

http://www.w3.org/2001/XMLSchema#string

Roger Paredes

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing in microfabricated high-density picolitre reactors

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.

Accuracy of the TRUGENE HIV-1 genotyping kit.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.

Clinically validated genotype analysis: guiding principles and statistical concerns.

Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

P304

662-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/650543

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41147301

http://www.w3.org/2001/XMLSchema#string

P698

20102271

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2825289

http://www.w3.org/2001/XMLSchema#string